Get the Daily Brief
Latest Biotech News
City of Hope Launches Generative AI Platform to Transform Cancer Care
City of Hope unveiled HopeLLM, a proprietary generative AI platform integrating multiple AI models with extensive oncology datasets to streamline clinical workflows and research. The application...
New Epigenomic Tools Illuminate Drug Mechanisms and Target Discovery
Foghorn Therapeutics’ Senior Director Dave Lahr highlights advances in epigenomic methods—CUT&RUN, ATAC-seq, and bisulfite sequencing—that enable high-resolution chromatin profiling to elucidate...
Kymera’s reshaped alliances: Gilead pact amid Sanofi shuffle
Kymera Therapeutics announced a significant licensing deal with Gilead Sciences to develop oral molecular glue degraders targeting proteins implicated in breast cancer. This partnership could...
FDA investigates Sarepta’s Elevidys after patient fatalities
Following two recent patient deaths caused by acute liver failure, the FDA has launched an investigation into Sarepta Therapeutics' gene therapy Elevidys for Duchenne muscular dystrophy. The...
Lilly’s tirzepatide to dominate GLP-1 drug market by 2030
Evaluate reports that total prescription drug sales are projected to reach $1.75 trillion by 2030, with GLP-1 receptor agonists constituting 9% of prescriptions. Eli Lilly's tirzepatide is...
Bristol Myers faces fresh antitrust suit over Pomalyst exclusivity
Bristol Myers Squibb is embroiled in a new 203-page antitrust lawsuit filed by insurance company Cigna, alleging BMS employed illegal tactics to preserve its monopoly on the multiple myeloma drug...
AI model AlphaGenome predicts gene regulation from DNA alterations
DeepMind introduced AlphaGenome, a comprehensive AI model designed to predict the effects of small DNA mutations on gene regulation and molecular processes. This marks an advance beyond protein...
Gene therapy mitochondrial base editing corrects pathogenic mutations
Researchers have successfully applied mitochondrial base editing (mtBE) to correct harmful mutations in mitochondrial DNA within patient-derived cells. Employing the DdCBE system, a...
City of Hope leverages generative AI for cancer care and research
City of Hope has developed HopeLLM, a proprietary generative AI platform that integrates diverse commercial and open-source AI models with extensive oncology data. The platform automates new...
Nuvalent advances ROS1 lung cancer drug towards FDA filing
Nuvalent reported promising efficacy data for zidesamtinib, its ROS1-targeted therapy for non-small cell lung cancer patients who have failed existing treatments. The drug achieved a 44% objective...
Nektar’s rezpegaldesleukin shows efficacy in atopic dermatitis phase 2b trial
Nektar Therapeutics reported positive Phase 2b results for rezpegaldesleukin (rezpeg), an IL-2 pathway agonist designed to stimulate regulatory T cells, in patients with moderate-to-severe atopic...
Breakthrough AI tool refines tumor cellular heterogeneity analysis
A multinational study led by the Garvan Institute unveiled AAnet, an advanced artificial neural network designed to characterize the complex cellular subpopulations within tumors, including...
AI powers City of Hope’s cancer care and research boost
City of Hope has launched HopeLLM, a generative AI platform integrating multiple AI models to streamline oncology workflows. The platform automates patient onboarding, facilitates clinical trial...
FDA leadership turnover amid regulatory shifts
The FDA is experiencing significant leadership changes impacting drug review and development. Acting CDER director Jacqueline Corrigan-Curay announced retirement following recent agency turnover,...
Nektar Therapeutics rebounds with positive phase 2b eczema data
Nektar Therapeutics reported promising Phase 2b results for rezpegaldesleukin, an IL-2 pathway agonist targeting atopic dermatitis. The drug demonstrated significant skin clearance improvements,...
Revolution Medicines secures $2 billion funding for RAS oncology pipeline
Revolution Medicines inked a flexible deal with Royalty Pharma for up to $2 billion to support global development and commercialization of its RAS(ON) inhibitor portfolio. The funding comprises...
Precision diagnostics advance with new AI and molecular tools
Multiple innovations are enhancing diagnostic precision in oncology and genomics. AI-driven tools like PromoterAI identify pathogenic promoter mutations contributing to genetic diseases. The...
Genetic and epigenetic breakthroughs impact disease understanding and therapy
Recent studies are elucidating molecular underpinnings of complex diseases. Research on SETD1B epigenetic regulation reveals its role in aggressive acute myeloid leukemia with FLT3-ITD mutation. A...
Cell and gene therapies show promising advancements in neurological and metabolic diseases
Innovative cell and gene therapy approaches demonstrate clinical potential. Vertex Pharmaceuticals' cell therapy zimislecel shows insulin independence in type 1 diabetes patients entering pivotal...
Environmental and agricultural innovations address sustainability challenges
Advances spanning climate resilience and agriculture are emerging. TUdi project introduces digital decision support tools to monitor soil health for regenerative agriculture globally. Cornell...